TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06628947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 μg KIO-301
Description: KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 μg KIO-301
Description: KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
Study: NCT05916144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction-Based Early Education Program
Description: The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
Study: NCT06077383

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weizmania Coagulans BC99
Description: Probiotics group subjects take probiotics every day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weizmania Coagulans BC99
Description: Probiotics group subjects take probiotics every day for 8 weeks.
Study: NCT06196814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
Description: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
Description: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
Description: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
Study: NCT05092997

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC viral load testing
Description: POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC viral load testing
Description: POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness visit services for male partners
Description: Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness visit services for male partners
Description: Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
Study: NCT04806724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opening the Conversation
Description: The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Side by Side
Description: The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
Study: NCT05104320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MICS-CABG
Description: Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sternotomy CABG
Description: Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
Study: NCT04847362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: education group
Study: NCT05083572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colonic lavage with polyethylene glycol
Description: The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colonic lavage with polyethylene glycol
Description: The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course.
Study: NCT06229340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: 100 mg daily for 3 days at the loading dose, then 20 mg daily at the standard dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab
Description: Use of one of the possible MEK-inhibitor options:~Trametinib 2 mg once daily orally; Cobimetinib 60 mg on days 1-21, break 7 days, cycle 28 days orally; Binimetinib 45 mg 2 times a day daily orally. + Hydroxychloroquine 600 mg 2 times a day daily orally.~± Bevacizumab 7.5 mg/m² every 3 weeks intravenously.
Study: NCT05136768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg, administered by intravenous infusion on the first day of each cycle, one cycle every 3 weeks (Q3W), with the maximum cycle of 17. Suspension of Sintilimab administration: patients's request, disease progression, researcher-evaluated SAE

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: At least one metastatic lesion is suitable for SBRT. If applicable, all metastatic lesions were allowed to be irradiated.~Recommended dose: BED ≥ 80Gy. Dose fractionation is determined as per physician's discretion, generally depending on the location of irradiated lesion and the distance to surrounding OARs.~Timing of SBRT: After completing at least 2 platinum-containing chemotherapy plus sintilimab treatments, SBRT can be started after assessing that there is no AE ≥ G2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Platinum based single or doublet chemotherapy, one cycle every 3 weeks (Q3W), 4-6 cycles.
Study: NCT05213650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-abrasive toothpaste
Description: Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abrasive toothpaste
Description: Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Efferdent
Description: Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaning Crystals
Description: Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
Study: NCT05872841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human adenovirus type 5 + TACE
Description: 1. Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose:~   ① The sum of the maximum diameters of the lesions was ≤10cm, and the total dose was 1. 0×1012vp (2 injections);~   ② The sum of the maximum diameters of the lesions was \>10cm, and the total dose was 1. 5×1012vp (3 injections);~2. TACE：The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply.~Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles.
Study: NCT05123768

Intervention type: DIAGNOSTIC_TEST
Intervention: NGS
Description: A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
Study: NCT05339568

Intervention type: OTHER
Intervention: Patients' whole process follow-up and management platform
Description: Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
Study: NCT04688853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TEG002
Description: TEG002 cells are autologous T cells transduced with a specific γδTCR
Study: NCT06140784

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% Sodium Monofluorophosphate Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT06362668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve Decongestion Management System
Description: The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)
Description: Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
Study: NCT05383781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip and Knee focused exercises
Description: Exercises which improves muscle strength, ROM
Study: NCT05210413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab in Pediatric cohort
Description: Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Pazopanib in Pediatric Cohort
Description: Oral pazopanib treatment at a fixed dose of 225mg/m²/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab in Adult cohort
Description: Infusion of 400 mg of spartalizumab on Day1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Pazopanib in Adult Cohort
Description: Oral pazopanib treatment with a fixed dose of 400 mg/day
Study: NCT06014021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback device
Description: Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about pelvic floor and communication with health professionals
Description: Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about pelvic floor and communication with health professionals
Description: Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about pelvic floor and communication with health professionals
Description: Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
Study: NCT06251544

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HTR2 T Cells
Description: Arm A -- Two dose levels will be evaluated:~Dose level One: 1.00E+06~Dose level Two: 1.00E+07

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HTR2 T Cells
Description: Arm B -- Two dose levels will be evaluated:~Dose level Two: 1.00E+07~Dose Level Three: 1.00E+08
Study: NCT05383781

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip and Knee focused exercises
Description: Exercises which improves muscle strength, ROM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short foot exercise
Description: The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
Study: NCT06435650

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cannabis suppositories and mindful-compassion for anal pain
Description: This is a combined intervention that includes mindful-compassion and cannabis suppositories for anal pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-compassion
Description: Mindful-compassion
Study: NCT05920642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine administration
Description: Administration of morphine into the spinal canal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral administration of analgesics
Description: Standard postoperative pain management of analgesics using parenteral route of administration.
Study: NCT05776355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKG2D CAR-NK
Description: Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
Study: NCT04037462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamthasone
Description: escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
Study: NCT06305819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management support program
Description: The SEMPO program is inspired by established self-management principles and established rehabilitation strategies. The program is manualized and integrates components from rehabilitation strategies within relevant functional domains. The program includes elements, such as tailored psychoeducational content, action planning, guided skills mastery, learning and practicing helpful compensatory strategies, problem solving techniques and sharing of experiences. The intervention is delivered by a multidisciplinary team and the participants are provided with written materials and a work book containing information about each session and work tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Treatment as usual
Study: NCT05741489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
Study: NCT05585879

Intervention type: DEVICE
Group type: OTHER
Intervention: Pure-Vu EVS
Description: Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~* Boston Bowel Preparation Score (BBPS) \< 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~* Inability to identify \> 5mm polyps
Study: NCT06237439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move with HaRT
Description: Move with HaRT is a group-based, manualized mind-body intervention.
Study: NCT06426875

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Isometric Exercises
Description: Isometric External Rotation (Perform isometric external rotation exercises with a resistance band to strengthen the rotator cuff.) Hold each contraction for 10-15 seconds. Isometric Internal Rotation (Hold each contraction for 10-15 seconds) Isometric Abduction (Supraspinatus). ( each contraction for 10 -15 sec) 10 repetition 3 sets Isometric Adduction (Subscapularis) Overhead Isometric Holds (Hold each contraction for 15-20 seconds) Isometric Shoulder External Rotation Against Resistance: (Hold each contraction for 15-20 seconds) Isometric Shoulder Press (Hold each contraction for 15-20 seconds) 15 to 20 repetitions 4 sets Total duration of 30 to 35 minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week
Study: NCT04834193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine-needle biopsy
Description: Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine-needle biopsy
Description: Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
Study: NCT04166591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overheard Speech
Description: New words are introduced with the child as a bystander rather directly taught.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Addressed Speech
Description: New words are introduced directly to the child by an experimenter.
Study: NCT06292195

Intervention type: OTHER
Intervention: Exposure
Description: Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)

Intervention type: OTHER
Intervention: Exposure
Description: Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)

Intervention type: OTHER
Intervention: Exposure
Description: Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
Study: NCT04949048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magneto PE Kit
Description: All enrolled patients will be treated with Magneto PE Kit
Study: NCT06217055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam based MAC
Description: The surgery will be performed under monitored anesthesia care by maintaining spontaneous breathing using remimazolam.